True however this stock has tons of shorters. I wouldn't trust the boards as to its appeal. When they get a drug approval the shorts will get pummeled. The company's products make a great platform for more development and there are no real major institutional holders which give it a long way to grow in terms of price appreciation. It is already impressive that they are one of the most traded stocks in the smaller exchanges.

Small and medium sixed businesses are going under or are being cannibalized and Washington doesn't seem to care.

Update:

"CytoDyn has long-term planning for its lead asset. The company reported that it has received the clearance from the Medicines & Healthcare product Regulatory Agency (MHRA) of the U.K. government to file Biologics License Application as a One injection per week treatment for multi-drug resistance HIV patients in the U.K.

Analysis: CytoDyn's lead asset leronlimab is set to be a major player in the CCR5 inhibitors/antagonist market. The company has a market capitalization of $1.38 billion on a stock price of $2.42, which is in the lower quadrant of the 52-week range from $0.26 to $10.01. Over 86% of the 571 million outstanding shares are held by the public, while institutions, corporations and insiders hold 4%, 3.7% and 5.68% shares respectively. CytoDyn has a debt of $32.4 million, and cash burn in the TTM has been $87.6 million, whereas cash balance is very low at $18.20 million"

seekingalpha.com/.../4383011-regenerons-positive-dupixent-data-and-news-good-bad-and-ugly-of-biopharma

Cytodyn HIV BLA in the UK news. www.globenewswire.com/.../...tion-HIV-Therapy.html

US oil production by small companies pumping at a loss has hurt US major oil producers and endangered the economies of Texas and others. It appears to be reckless and without regard to the long term interests of the US. Of course banks are partially to blame for lending to companies to drill and keep pumping with no hopes of gaining profitability with such heavy debt loads. There needs to be some sort of regulation on banks and lenders to prevent them from preying on this industry.

I think this has more to do with American's tendency towards a positive outlook than expressing their true economic states and outlooks. It is pretty obvious the average American is not economically better off, especially if you take into account inflation and the higher cost of medical treatment. That said, who wants to say they are falling behind? We tend to want to view our plight as improving even if that is not the actual fact.

That's probably why they are able to do it. Anyways its pocket change to them which they can afford from getting free money from your pocket for funding their "vaccine" Easter egg hunt where the government pays for their R&D and buys stuff that may be useless. Still I wouldn't be surprised if they fund shorters. That's the way they buy up bio-pharmas cheaply after they do all the work to develop novel stuff.

Thanks. It's so interesting to see the shorters havoc over good news. CYDY keeps plodding on to approvals everywhere. Hopefully, the company will dispel more inaccuracies at their 5:00 PM conference call and others pick up on the good news.

We will see what CYDY has in store for announcing this news on the call at 5:00 PM. I hope they dispel the ranting and raving of shorts claiming absurdities again. It is funny they didn't do this on all the Covid drug failures by big pharma. Let science be the guide, not speculation. CYDY keeps plugging away and making headway.

Here's an update.

www.cytodyn.com/.../cytodyn-receives-positive-dsmc-recommendation-after-interim

www.zerohedge.com/.../unrecognized-therapeutic-takes-dying-covid-19-table-30000-american-lives-hanging

Interim results were good. However they want the study finished. In reality this provides a clear path to approval with a positive finding half way through. It is sad so many are dying while we lollygag through approvals with a drug that has been proven to save some lives with an extremely high safety profile.